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Beim Border Collie wird ein erblicher Cobalaminmangel vermutet. Die Diagnose 
beruht auf einer tiefen Cobalamin- und einer erhöhten Homozysteinkonzentration im 
Blut sowie auf einer erhöhten Methylmalonsäurekonzentration im Urin. Ziele dieser 
Studie waren (1) Referenzwerte für Cobalamin und Homozystein im Blut sowie für 
Methylmalonsäure im Urin (ausgedrückt als Quotient zum Kreatinin) zu erstellen und 
(2) Border Collies mit Hilfe dieser Parameter zu untersuchen. 
Cobalamin wurde mittels Chemilumineszenz-Assay, Homozystein mittels HPLC mit 
fluorimetrischer Detektion und Methylmalonsäure mittels Gaschromatographie / 
Massenspektrometrie bestimmt. Insgesamt wurden 35 gesunde Hunde diverser 
Rassen und 113 Border Collies in die Studie aufgenommen. Vier Border Collies litten 
an einem Cobalaminmangel mit folgenden Wertebereichen: Cobalamin < 150 
(Referenzbereich (Ref), 261.2–1001) ng/L, Homozystein 40–81.6 (Ref, 4.3–18.4) 
µmol/L und Methylmalonsäure 1800–6665 (Ref, < 4.2) mMol/Mol. Interessanterweise 
wiesen 37.7% der Border Collies mit normalem Cobalamin eine erhöhte 
Methylmalonsäurekonzentration auf (P  < 0.0001). Zusammengefasst weist der 
Befund der Methylmalonazidurie bei Border Collies mit einer normalen 
Cobalaminkonzentration als auch bei solchen mit einem Cobalaminmangel auf 2 
verschiedene biochemische Defekte hin. Studien, die die Cobalaminabsorption und 
dessen Stoffwechselwege untersuchen, sind indiziert. 
 
 






Hereditary cobalamin deficiency is suspected in the Border Collie breed. Diagnosis is 
based on hypocobalaminemia, hyperhomocysteinemia and methylmalonic aciduria.  
Goals of the study were (1) to establish reference values for the blood concentrations 
of cobalamin and homocysteine and for the concentration of urinary methylmalonic 
acid and (2) to screen a larger Border Collie population with the aforementioned 
markers. 
Cobalamin, homocysteine and methylmalonic acid were measured using an 
automated chemiluminescence assay, HPLC with fluorimetric detection and gas 
chromatography / mass spectrometry. A total of 113 Border Collies and 35 healthy 
dogs of different breeds were examined. Four Border Collies suffered from cobalamin 
deficiency with the following concentrations: cobalamin < 150 (reference range (ref), 
261–1001) ng/L, homocysteine 40–81.6 (ref, 4.3–18.4) µmol/L, and methylmalonic 
acid 1800–6665 (ref, < 4.2) mmol/mol. Unexpectedly 37.7% of Border Collies with 
normal cobalamin had significantly higher methylmalonic acid concentrations (P < 
0.0001). In conclusion, the simultaneous finding of methylmalonic aciduria in Border 
Collies with normal cobalamin concentrations in addition to Border Collies with 
clinicopathologic findings of cobalamin deficiency is surprising and suggests two 
different defects. Future studies investigating the absorption process as well as the 
metabolic pathway of cobalamin are warranted. 
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Objective–To establish reference values for serum cobalamin (Cbl), urinary 
methylmalonic acid/creatinine ratios (uMMA/Cr) and plasma total homocysteine 
(tHcy) in healthy pet dogs and to evaluate these biomarkers in the Border Collie 
(BC), a breed in which hereditary cobalamin deficiency (CD) has been described. 
 
Animals–One hundred thirteen BC and 35 control dogs. 
Procedures–Prospective study. Serum Cbl, urinary MMA and plasma tHcy were 
measured using an automated chemiluminescence assay, gas 
chromatography/mass spectrometry, and HPLC with fluorimetric detection, 
respectively.  
Results–Four BC with Cbl concentrations below the detection limit of 150 ng/L 
(reference range, 261–1001) were identified. In these 4 BC the median uMMA/Cr 
was 4064 mmol/mol (reference range, < 4.2), and the median tHcy was 51.5 µmol/L 
(reference range, 4.3–18.4). Clinicopathologic signs included stunted growth, 
lethargy, anemia, and proteinuria. All dogs improved markedly with regular Cbl 
supplementation. Of the 109 healthy BC with normal Cbl and tHcy values, 41 (37.7%) 
had significantly (P < 0.0001) higher uMMA/Cr compared to control dogs ranging 
from 5 to 360 mmol/mol.  
Conclusions and Clinical Relevance–Hereditary CD is a rare disease with variable 
clinical signs in the BC. The concurrent finding of methylmalonic aciduria in healthy 
eucobalaminemic BC in addition to sick BC diagnosed with CD is surprising and 
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suggests two different defects: intestinal Cbl malabsorption or defects in the 
intracellular processing of Cbl. Future studies investigating the absorption process as 
well as the metabolic pathway of Cbl are warranted.  
 
Abbreviations 
BC  Border Collie 
CBC     Complete blood cell count 
Cbl  Cobalamin 
CD  Cobalamin deficiency 
CV   Coefficient of variation  
uMMA/Cr  Urinary methylmalonic acid/creatinine ratio 

















Cobalamin (Cbl) (vitamin B12) is an essential cofactor for several enzyme systems in 
mammalian species, and adequate amounts are required for nucleic acid synthesis.1 
Animals are unable to synthesize Cbl and therefore entirely dependent upon 
adequate  
dietary sources.1 The absorption of Cbl is complex, as it is first bound to haptocorrin, 
then to gastric or pancreatic intrinsic factor, and finally transferred to specific 
receptors located on the ileal enterocytes.2 Hypocobalaminemia can develop for 
several reasons, including pancreatic and intestinal disease.3 In humans, cobalamin 
deficiency (CD) due to selective malabsorption is a rare autosomal-recessive 
hereditary disorder appearing initially in early childhood.4,5 In dogs, hereditary CD has 
been reported in Giant Schnauzers, Australian Shepherds, and in Chinese Shar 
Peis.6-8 Moreover, CD has been repeatedly described in the Border Collie (BC) 
breed,9-11 as well as in one Beagle.12 Cobalamin acts as a co-factor in the conversion 
of methylmalonyl-CoA to succinyl-CoA via the enzyme methylmalonyl-CoA mutase 
and is needed for the re-methylation of homocysteine via the enzyme methionine 
synthase.1 Deficiency of Cbl leads to reduced activity of both of these enzymes 
resulting in an increase of methylmalonic acid (MMA) and total homocysteine (tHcy).1 
Measurement of these metabolites allows the assessment of cellular Cbl availability 
and is the test of choice to detect early or mild CD in humans.13 Correlations of 
urinary methylmalonic acid/creatinine (MMA/Cr) ratios and plasma tHcy with serum 
Cbl levels have not been investigated in dogs so far. Also, existing reference ranges 
for Cbl have not been compared with concurrent measurements of these cellular 
markers. After having diagnosed CD in BC presenting with nonspecific clinical signs, 
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the authors hypothesized that this deficiency might be more prevalent than actually 
recognized. 
Thus the goals of this study were (1) to establish reference values for serum Cbl, 
urinary uMMA/Cr and tHcy in healthy pet dogs and (2) to evaluate these markers of 
























Materials and Methods 
This study was approved by the Committee for the Permission of Animal 
Experimentation, Canton of Zurich, Zurich, Switzerland. 
 
BC–Between July 2009 and September 2010, 113 purebred BC were screened for 
CD. Dog owners were recruited for participation through the Swiss BC homepage, 
articles in Swiss dog magazines and through informed referring veterinarians. 
Assessment of all dogs included a detailed history, physical examination, complete 
blood cell count (CBC), serum biochemistry and urinalysis. 
 
Control dogs from other breeds–Thirty-five healthy dogs were recruited as 
controls. Inclusion criteria were (1) being a breed other than a BC or BC cross (2) no 
history of disease in the past 12 months and judged to be healthy by their owners (3) 
normal physical examination (4) unremarkable CBC, serum biochemistry, and 
complete urinalysis. The group consisted of 19 mixed-breed dogs, 3 Labrador 
Retrievers, 2 Golden Retrievers, and 11 other pedigree breeds. The median age was 
5 years (range, 1–15), and the median bodyweight was 12.6 kg (range, 5.1–43). 
There were 9 female, 5 male, 9 spayed female and 12 neutered male dogs. 
All dogs were fasted 8 to 12 hours before blood sampling. Urine samples were 
collected by the owner in the evening or morning before the examination. A paired 
urine sample (fasted and 8 h post standard meal) for assessment of the effect of prior 
food intake on urinary MMA excretion was analyzed in 6 dogs. 
Serum Cbl, urine uMMA/Cr und plasma tHcy concentrations were additionally 
determined in 12 supplementary healthy dogs that were exclusively fed bone and raw 
food. Breeds included 2 Australian Shepherds, 1 Jack Russell Terrier, 1 Alaskan 
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Malamute, 1 Tervueren, 1 Airedaile Terrier and 6 mixed-breed dogs. The median age 
was 5.4 years (range 1.9–13.3) and the median bodyweight was 22.7 kg (range, 6.1–
39.7). There were 1 female, 1 male, 7 spayed female and 3 neutered male dogs.  
 
Serum Cbl, plasma tHcy, and uMMA/Cr–Serum Cbl was measured using an 
automated chemiluminescence assaya as described before.8 The upper limit of 
detection of this assay is 1,000 ng/L, and serum samples were diluted 1:2 or higher if 
necessary. The in-house intra- and interassay coefficients of variation (CV) for canine 
serum samples were 2.1% and 3.4%, respectively. The lower detection limit of the 
assay is 150 ng/L. 
Plasma tHcy was measured using high performance liquid chromatography (HPLC) 
and fluorimetric detection.14 Blood samples, collected in pre-chilled sodium citrate 
tubes, were immediately centrifuged at 1570 g at 4°C for 10 min. The plasma was 
separated and stored at -80°C until assayed. Homocysteine was added to a canine 
citrate plasma pool to give a concentration of 100 µmol/L. This pool sample was 
sequentially diluted to give standards of 50, 25, 12.5, 5.0 and 2.5 µmol/L (aliquots 
were stored at -80°C) and a standard curve was run with each batch of samples. 
Recoveries were tested by including 3 standards (25, 12.5 and 5.0 µmol/L) as 
samples five times during a 3-week period. The recoveries were > 96% for each 
standard tested. As no quality control material for tHcy is commercially available in 
canine samples, we included a canine plasma pool in each run (mean concentration 
= 16.8 µmol/L). The between run CV for this sample was < 6%. The within batch CV 
was < 3% at a concentration of 50 µmol/L and < 6% at 5 µmol/L. The lower limit of 
detection was 2.5 µmol/L. 
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Urinary MMA was determined by gas chromatography/mass spectrometryb with a 
lower limit of detection of 0.15 mmol.15 Results were expressed per mol of urinary 
creatinine. Creatinine was measured by the Jaffe method using an ABXPentra 400 
analyzer.c This method had been validated for canine samples using the same 
instrument at the University School of Veterinary Medicine, Giessen, Germany.  
 
Statistical analysis–Data were analyzed using GraphPad PRISM 5.0.d Each data 
set was evaluated for normality by Kolmogorov-Smirnov test. Within the two groups 
Cbl, uMMA/Cr, tHcy, results of CBC and serum biochemistry were compared using 
the Mann-Whitney U-test. The Spearman’s rank correlation coefficient was used to 
determine a relationship between uMMA/Cr, Cbl and tHcy in both groups. Values of 
P < 0.05 were considered statistically significant. Reference ranges were established 
using the nonparametric percentile method. The 2.5 and 97.5 percentiles were 
determined to achieve the 95% double-sided reference interval in case of Cbl and 
tHcy. Regarding uMMA/Cr, the 95th percentile was used to obtain the one-sided 
reference range. Serum Cbl concentrations and uMMA/Cr outside the working range 











Control dogs–Serum Cbl concentrations ranged from 261–1001 ng/L (median, 441 
[mean ± SD; 540.5 ± 235.5] Figure 1). The established reference range was 261–
1001 ng/L, calculated from the central 95th percentile.  
Urinary MMA/Cr ranged from < 2–6.6 mmol/mol (median, 1.9 [mean ± SD; 2.1 ± 0.8] 
Figure 2); 32 dogs had uMMA/Cr < 2 mmol/mol, 2 dogs had 2.5 and 3.6 mmol/mol 
respectively. The established upper reference limit was 4.2 mmol/mol. Previous food 
intake had no effect on uMMA/Cr in 6 dogs; all paired samples were < 2 mmol/mol.  
Plasma tHcy concentrations ranged from 4.3–18.4 μmol/L (median, 9.1 [mean ± SD; 
10.4 ± 4.5] Figure 3). The calculated reference range (central 95th percentile) was 
4.3–18.4 μmol/L. 
No correlation was detected with the Spearman’s rank correlation coefficient between 
Cbl and tHcy as well as between Cbl and uMMA/Cr and uMMA/Cr and tHcy.  
Results of dogs that were exclusively fed bone and raw food did not differ from 
results of control dogs.  
 
Border Collies 
Healthy BC–Data of 109 healthy BC were analyzed. None of the dogs received any 
supplements at the time of the study. All dogs were physically in athletic shape and 
no abnormalities were noted upon clinical examination. Hematologic, biochemical, 
and urine examinations were unremarkable in all 109 dogs. The median age was 4 
years (range, 0.2–14) and the total group consisted of 32 intact male, 30 intact 
female, 28 spayed female and 19 neutered male dogs. The median body weight was 
17.3 kg (range, 2.7–29). The median serum Cbl concentration was 592 ng/L (range, 
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150–1855 [mean ± SD; 641.4 ± 304.5] Figure 1), which was not significantly different 
compared to control dogs.  
Urinary MMA/Cr ranged from < 2–360 mmol/mol (median, 1.9 [mean ± SD; 23.7 ± 
60.1] Figure 2), 47 (43.1%) BC had results > 2 mmol/mol (range, 3.2–360 mmol/mol) 
and 41 (37.7%) had uMMA/Cr above the upper reference limit of 4.2 mmol/mol. The 
uMMA/Cr were significantly higher (P < 0.0001) compared to controls.  
The urinary creatinine concentrations of 41 BC with elevated uMMA/Cr were not 
significantly different compared to 68 BC with uMMA/Cr within the reference range. 
Plasma tHcy values ranged from 2.8–22.4 µmol/L (median, 8.5 [mean ± SD; 9.5 ± 4] 
Figure 3) and were not different from those of control dogs. 
Five healthy BC had Cbl values below the reference range (261–1001 ng/L) ranging 
from 150–259 ng/L (median, 251). All of these 5 BC had uMMA/Cr and tHcy values 
within the reference range. 
Cbl and tHcys concentrations of the 47 healthy BC with uMMA/Cr > 2 mmol/mol did 
not differ significantly compared to controls. The Spearman’s rank correlation 
coefficient did not reveal any correlation between the aforementioned three 
parameters (Cbl, tHcys, uMMA/Cr) in all healthy BC as well as in BC with uMMA/Cr 
above the upper reference limit. 
 
BC with CD–CD was diagnosed in 4/113 BC. The median age was 11.5 months (8–
42), the median weight was 11.6 kg (11–12.1) and all dogs were intact females. All 
dogs had serum Cbl concentrations < 150 ng/L (Figure 1), the median uMMA/Cr was 
4064 mmol/mol (range, 1800–6665; Figure 2), and the median plasma tHcy 
concentration was 51.5 µmol/L (range, 40–81.6; Figure 3). All 4 dogs were fed 
different commercial dog foods.  
 14
Affected BC exhibited growth failure (4/4), lethargy (4/4), glossitis (2/4), febrile 
episodes (1/4), mild non-regenerative anemia (3/4), neutropenia (1/4), isolated 
elevated aspartate aminotransferase activities (3/4) and mild proteinuria (4/4). 
Parenteral cobalamin administration produced complete remission of all 
clinicopathologic abnormalities, even though proteinuria and isolated aspartate-






















To the authors knowledge, serum Cbl concentrations in direct comparison with its 
cellular biomarkers MMA and tHcy have not been evaluated in healthy pet dogs so 
far. Details of currently used reference ranges have not been published. Results of 
the additional measurements of these Cbl biomarkers confirm the hitherto existing 
serum Cbl reference range. Although no biochemical gold standard exists to predict 
Cbl status, a normal MMA value in humans is generally considered supportive of a 
normal Cbl status, even when Cbl concentration is low.16 Little is known about MMA 
in dogs. Elevated serum MMA concentrations predicted serum Cbl status in cats and 
decreased again with Cbl supplementation.17 Similarly, Berghoff et al. recently 
documented a negative correlation between serum Cbl and serum MMA 
concentrations in dogs.18 Results of that study also suggested that measurement of 
serum MMA concentration may be a better diagnostic test for CD than serum Cbl 
concentration. Urinary MMA has only sporadically been measured, and no reference 
ranges have been established so far.9,10,12,19 Measurement of uMMA/Cr may have 
several advantages. Firstly, MMA values in urine are up to 40 fold higher than in 
serum and therefore easy to detect.20 Secondly, urinary MMA is expressed as a ratio 
to urinary creatinine, thereby minimizing influences from hemoconcentration and 
kidney disease.20,21 Thirdly, MMA is very stable in urine,22 whereas no data exist on 
serum MMA stability. Lastly, a free catch urine sample might be less invasive and 
easily obtainable by owners compared to blood sampling. 
Unexpectedly, uMMA/Cr in healthy BC were significantly higher compared to 
controls. Causes for elevated uMMA/Cr in people include prior food intake, although 
postprandial levels have only been shown to rise as high as 3 mmol/mol.23 A diet-
induced effect seems unlikely in our study as sampling conditions were identical for 
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both groups. Furthermore, uMMA/Cr investigated separately in 6 staff-owned dogs 
before and after feeding a standard meal did not differ. Even if diet had a minor 
impact on elevated uMMA/Cr of healthy BC, our observed values are still much 
higher than those reported in non-fasted humans.23  
Theoretically, small intestinal bacterial overgrowth may also increase urinary MMA 
excretion. An overgrowth of bacteria producing propionic acid, a precursor of 
methylmalonyl-CoA, could lead to increased formation of urinary MMA.24 The authors 
cannot fully exclude this possibility, but deem this rather unlikely, as none of the 
healthy BC had a history of digestive problems. Most notably, feeding patterns did 
not differ between control dogs and BC. 
Extremely high uMMA/Cr (237, 264, and 360 mmol/mol) were found in 3 healthy un-
related BC living in the same household. All dogs were fed with bone and raw food. 
Because feeding bone and raw food usually comprises a freeze-thaw process, loss 
of water-soluble B vitamins was suspected. In order to clarify this, serum Cbl, and 
plasma tHcy concentrations as well as uMMA/Cr of 12 additional healthy pet dogs 
exclusively fed bone and raw food were determined. Results did not differ compared 
to control dogs.  
It is possible that the healthy eucobalaminemic BC with methylmalonic aciduria 
represent subclinical carriers of hereditary selective Cbl malabsorption. Genetic 
testing would be required to verify this hypothesis. However lacking differences in 
serum Cbl and plasma tHcy concentrations between control dogs and healthy BC 
make a carrier status appear less likely.  
In humans, inborn errors of cellular Cbl metabolism are further reasons for 
methylmalonic aciduria.25,26 Intracellular Cbl metabolism involves multiple steps 
between the lysosomal release of Cbl and the synthesis of adenosylcobalamin in the 
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mitochondria (required by the mitochondrial enzyme methylmalonyl-CoA mutase) and 
methylcobalamin in the cytosol (required by the cytoplasmic enzyme methionine 
synthase). To date, nine distinct defects of this pathway have been defined in 
humans leading either to isolated methylmalonic aciduria or to isolated 
homocysteinemia or both, depending on which step in metabolism is affected.25,26 In 
these individuals, Cbl levels are usually in the reference range, as observed in our 
healthy BC group. However, in people the majority of defects are usually associated 
with overt clinical signs, leading to life-threatening disease, whereas asymptomatic 
affected individuals with methylmalonic aciduria are very rare.26 
In this regard, our observation of increased uMMA/Cr in 37.7% of all screened BC 
could represent a rare phenomenon called benign methylmalonic aciduria. Benign 
methylmalonic aciduria has been reported in children without evidence of CD and 
without response to the administration of Cbl.27 Two siblings in that study, were found 
to have a defect in the methylmalonyl-CoA mutase enzyme.27 Another report 
described benign methylmalonic aciduria in a Turkish family, where three family 
members had normal serum Cbl concentrations, normal plasma and urine tHcys 
concentrations. Results of an extended biochemical screening for other known 
causes of methylmalonic aciduria were all normal, including an intact methylmalonyl-
CoA mutase system.28 
All BC with CD had elevated plasma tHcy concentrations compared to controls. 
Homocysteine is the intermediate product of methionine metabolism; its further 
metabolism is Cbl-dependent. Homocysteine is a very sensitive indicator of CD in 
humans and levels rise early in the course of disease often preceding clinical signs. 
Renal disease, hemoconcentration, thyroid disease, folate deficiency and drugs are 
known causes for hyperhomocysteinemia.29 Similarly increased tHcy levels were 
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associated with renal and cardiac diseases in one study in dogs.30 None of these 
potential causes were found in the BC with CD. 
Interestingly none of the 41 healthy BC dogs with elevated uMMA/Cr had elevated 
tHcy values, thus making a subclinical defect in the methylmalonic-CoA mutase more 
likely. 
Hypocobalaminemia (range, 150–259 ng/L; median, 251 [reference range 261-1001]) 
was also documented in 5 healthy BC with 4 dogs having nearly normal Cbl values 
(230, 251, 254, and 259 ng/L). Unlike the 4 diseased BC with CD, these 
hypocobalaminemic healthy BC had normal uMMA/Cr and plasma tHcy values. Also 
in sharp contrast to the diseased BC, these dogs were in excellent physical and 
clinical condition. The possibility of enzyme-bound tissue Cbl preventing cellular 
deficiency further indicates the necessity to measure cellular Cbl markers.12  
In conclusion, the concurrent finding of isolated methylmalonic aciduria in healthy BC 
with normal Cbl concentrations and sick BC suffering from CD is intriguing and awaits 
further clarification. These results may suggest different disease processes: A defect 
in the mitochondrial metabolic pathway of Cbl (i.e. methylmalonyl-CoA mutase) on 
the one hand, and a selective intestinal malabsorption of Cbl on the other hand. 
Future studies should focus on genetic testing, intestinal Cbl absorption, as well as 









a. Immulite 2000, Vitamin B12, Siemens Healthcare Diagnostics Inc. 
b. Shimadzu QP5050A. 
c. AxonLab, Stuttgart, Germany. 























1. Markle HV. Cobalamin. Crit Rev Clin Lab Sci 1996;33:247-356. 
2. Marcoullis G, Rothenberg SP. Intrinsic factor-mediated intestinal absorption of 
cobalamin in the dog. Am J Physiol 1981;241:294-299. 
3. Batt RM, Morgan JO. Role of serum folate and vitamin B12 concentrations in the 
differentiation of small intestinal abnormalities in the dog. Res Vet Sci 1982;32:17-22.  
4. Grasbeck R, Gordin R, Kantero I, et al. Selective vitamin B12 malabsorption and 
proteinuria in young people. A syndrome. Acta Med Scand 1960;167:289-296. 
5. Imerslund O. Idiopathic chronic megaloblastic anemia in children. Acta Paediatr 
Suppl 1960;49:1-115.  
6. Fyfe JC, Hall CA, Jezyk PF, et al. Inherited selective intestinal cobalamin 
malabsorption and cobalamin deficiency in dogs. Pediatr Res 1991;29:24-31. 
7. He Q, Madsen M, Kilkenney A, et al. Amnionless function is required for cubilin 
brush-border expression and intrinsic factor-cobalamin (vitamin B12) absorption in 
vivo. Blood 2005;106:1447-1453.  
8. Grützner N, Bishop MA, Suchodolski JS, et al. Association study of cobalamin 
deficiency in the Chinese Shar Pei. J Hered 2010;101:211-217. 
9. Morgan LW, McConnell J. Cobalamin deficiency associated with erythroblastic 
anemia and methylmalonic aciduria in a border collie. J Am Anim Hosp Assoc 
1999;35:392-395. 
10. Battersby IA, Giger U, Hall EJ. Hyperammonaemic encephalopathy secondary to 
selective cobalamin deficiency in a juvenile Border collie. J Small Anim Pract 
2005;46:339-344. 
 21
11. Outerbridge CA, Myers SL, Giger U. Hereditary Cobalamin Deficiency in Border 
Collie Dogs. J Vet Intern Med 1996;10:169. 
12. Fordyce HH, Callan MB, Giger U. Persistent cobalamin deficiency causing failure 
to thrive in a juvenile beagle. J Small Anim Pract 2000;41:407-410. 
13. Savage DG, Lindenbaum J, Stabler SP, et al. Sensitivity of serum methylmalonic 
acid and total homocysteine determinations for diagnosing cobalamin and folate 
deficiencies. Am J Med 1994;96:239-246. 
14. Vester B, Rasmussen K. High performance liquid chromatography method for 
rapid and accurate determination of homocysteine in plasma and serum. Eur J Clin 
Chem Clin Biochem 1991;29:549-554. 
15. Sewell AC, Böhles HJ. 4-Hydroxycyclohexanecarboxylic acid: a rare compound in 
urinary organic acid analysis. Clin Chem 1991;37:1301-1302. 
16. Vogiatzoglou A, Oulhaj A, Smith AD, et al. Determinants of plasma methylmalonic 
acid in a large population: implications for assessment of vitamin B12 status. Clin 
Chem 2009;55:2198-2206.  
17. Ruaux CG, Steiner JM, Williams DA. Early biochemical and clinical responses to 
Cbl supplementation in cats with signs of gastrointestinal disease and severe 
hypocobalaminemia. J Vet Intern Med 2005;19:155-160. 
18.  Berghoff N, Suchodolski JS, Steiner JM. Association of serum Cbl and 
methylmalonic acid concentrations in dogs. Vet J 2011 Apr 6. [Epub ahead of print] 
19. Fyfe JC, Jezyk PF, Giger U, et al. Inherited selective malabsorption of vitamin 
B12 in Giant Schnauzers. J Am Anim Hosp Assoc 1989;25:533-539. 
20. Norman EJ, Cronin C. Cobalamin deficiency. Neurology 1996;47:310-311. 
 22
21. Norman EJ. Urinary methylmalonic acid/creatinine ratio: a gold standard test for 
tissue vitamin B12 deficiency. J Am Geriatr Soc 1999;47:1158-1159.  
22. Matchar DB, Feussner JR, Millington DS, et al. Isotope-dilution assay for urinary 
methylmalonic acid in the diagnosis of vitamin B12 deficiency. A prospective clinical 
evaluation. Ann Intern Med 1987;106:707-710. 
23. Rasmussen K. Studies on methylmalonic acid in humans. I. Concentrations in 
serum and urinary excretion in normal subjects after feeding and during fasting, and 
after loading with protein, fat, sugar, isoleucine, and valine. Clin Chem 1989;35:2271-
2276. 
24. Bain MD, Jones M, Borriello SP, et al. Contribution of gut bacterial metabolism to 
human metabolic disease. Lancet 1988;1:1078-1079.  
25. Whitehead VM. Acquired and inherited disorders of cobalamin and folate in 
children. Br J Haematol 2006;134:125-136. 
26. Watkins D, Rosenblatt DS. Inborn errors of cobalamin absorption and 
metabolism. Am J Med Genet C Semin Med Genet 2011;157:33-44. 
27. Ledley FD, Levy HL, Shih VE, et al. Benign methylmalonic aciduria. N Engl J Med 
1984;311:1015-1018. 
28. Sewell AC, Herwig J, Böhles H. A case of familial benign methylmalonic aciduria? 
J Inherit Metab Dis 1996;19:696-697. 
29. Stanger O, Herrmann W, Pietrzik K, et al. DACH-LIGA homocystein (german, 
austrian and swiss homocysteine society): consensus paper on the rational clinical 
use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic 
diseases: guidelines and recommendations. Clin Chem Lab Med 2003;41:1392-
1403. 
 23
30. Rossi S, Rossi G, Giordano A, et al. Homocysteine measurement by an 
enzymatic method and potential role of homocysteine as a biomarker in dogs. J Vet 





































Figure 1–Scatterplot showing results of serum Cbl concentration for BC (n = 113) and 
control dogs (n = 35). Asterisks indicate the 4 Cbl-deficient BC. Median values are 


























Figure 2–Results of uMMA/Cr of BC (n = 113) and control dogs (n= 35). Asterisks 
indicate the 4 Cbl-deficient BC. The line indicates the median value. The established 
upper reference limit was < 4.2 mmol/mol creatinine. uMMA/Cr of 109 healthy BC 






Figure 3–tHcy concentrations of BC (n = 113) and control dogs (n = 35). Asterisks 
indicate the 4 Cbl-deficient BC. The line indicates the median value. The established 
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